Response: Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled-release carbamazepine in noninferiority epilepsy monotherapy trials: How much "fair" is "fair"

Eugen Trinka (First author), JF Rocha, P Soares-da-Silva

Research output: Contribution to journalLetter to the editorpeer-review

Original languageEnglish
Pages (from-to)900-901
JournalEPILEPSIA
Volume59
Issue number4
DOIs
Publication statusPublished - 2018

Keywords

  • NEWLY-DIAGNOSED EPILEPSY
  • NON-INFERIORITY TRIAL
  • DOUBLE-BLIND
  • EFFICACY
  • TOLERABILITY
  • PHASE-3
  • SAFETY

Cite this